PPARG and glioblastoma: In summary, the pan-cancer analysis and experimental investigations of PPARG have confirmed its differential expression across various types of cancers and its association with survival outcomes and poor prognosis, including in PAAD, LIHC, LGG, GBM, and other types of cancer.